Phase 3 long-term study of K-911 (bimatoprost grenod) in patients with primary open-angle glaucoma (broad definition), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension

开始日期2025-06-01

申办/合作机构

Kowa Co., Ltd.

NCT05938699

/ Completed临床2/3期

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution - A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial (Whistler)

This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.

开始日期2023-12-12

申办/合作机构

Nicox Ophthalmics, Inc.

100 项与格贝前列素相关的临床结果

登录后查看更多信息

100 项与格贝前列素相关的转化医学

登录后查看更多信息

100 项与格贝前列素相关的专利（医药）

登录后查看更多信息

项与格贝前列素相关的文献（医药）

2024-12-01·Contemporary Clinical Trials

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

Article

作者: Mansberger, Steven L ; Hubatsch, Doug ; Fechtner, Robert ; Lopez, Krisi

PURPOSE:

To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

PATIENTS AND METHODS:

In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.1 %, or latanoprost 0.005 % dosed topically to both eyes once daily. After at least 30 subjects were assigned to each group, interim analysis was undertaken at 2 weeks and an independent committee selected the final NCX 470 dose for the full 12-week trial.

RESULTS:

The interim analysis included 103 subjects. The least-squares mean (95 % confidence interval [CI]) difference in diurnal intraocular pressure (IOP) was -1.51 mmHg (-2.88, -0.14) in the NCX 470 0.065 % group (p = 0.0308) and - 1.71 mmHg (-3.04, -0.38) in the NCX 470 0.1 % group (p = 0.0123), both favoring NCX 470 over latanoprost. The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). NCX 470 0.1 % was selected as the final dose and the NCX 470 0.065 % dose arm was terminated with subsequent subjects randomized 1:1 to NCX 470 0.1 % or latanoprost.

CONCLUSION:

Both concentrations of the NO-donating bimatoprost NCX 470 lower IOP more than latanoprost following 2 weeks of daily therapy. This adaptive dose selection design allowed identification of the optimal dose of NCX 470 with reduced trial costs, recruitment time, and the number of patients exposed to study medication.

2024-08-01·Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs

Article

作者: Unser, Andrea ; Torrejon, Karen Y. ; Ahmed, Feryan ; Torrejon, Karen Y ; Impagnatiello, Francesco ; Hubatsch, Douglas A ; Bastia, Elena ; Hubatsch, Douglas A. ; Galli, Corinna ; Toris, Carol ; Fan, Shan

Purpose: To determine NCX 470 (0.1%) and Lumigan^® (bimatoprost ophthalmic solution, 0.01%-LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics. Methods: Ocular hypotensive activity of NCX 470 and LUM was compared with vehicle (VEH) in Beagle dogs using TonoVet^®. Non-human primates (NHP) and bioengineered three-dimensional (3D) human Trabecular Meshwork/Schlemm's Canal (HTM/HSC™) constructs exposed to transforming growth factor-β2 (TGFβ2) were used to monitor NCX 470 and LUM-induced changes in AH dynamics. Results: NCX 470 (30 μL/eye) showed greater IOP reduction compared with LUM (30 μL/eye) following single AM dosing [maximum change from baseline (CFB_max) = -1.39 ± 0.52, -6.33 ± 0.73, and -3.89 ± 0.66 mmHg (mean ± standard error of the mean) for VEH, NCX 470, and LUM, respectively]. Likewise, repeated 5 days daily dosing of NCX 470 resulted in lower IOP than LUM across the duration of the study (average IOP decrease across tests was -0.45 ± 0.22, -6.06 ± 0.15, and -3.60 ± 0.22 mmHg for VEH, NCX 470, and LUM, respectively). NCX 470 increased outflow facility (Cfl) in vivo in NHP (Cfl_VEH = 0.37 ± 0.09 μL/min/mmHg and Cfl_NCX470 = 0.64 ± 0.17 μL/min/mmHg) as well as in vitro (C_HTM/HSC) in HTM/HSC constructs (C_HTM/HSC__VEH = 0.47 ± 0.02 μL/min/mm²/mmHg and C_HTM/HSC__NCX470 = 0.76 ± 0.03 μL/min/mm²/mmHg). In addition, NCX 470 increased uveoscleral outflow (Fu_VEH = 0.62 ± 0.26 μL/min and Fu_NCX470 = 1.53 ± 0.39 μL/min with episcleral venous pressure of 15 mmHg) leaving unaltered aqueous flow (AHF_VEH = 2.03 ± 0.22 μL/min and AHF_NCX470 = 1.93 ± 0.31 μL/min) in NHP. Conclusions: NCX 470 elicits greater IOP reduction than LUM following single or repeated dosing. Data in NHP and 3D-HTM/HSC constructs suggest that changes in Cfl and Fu account for the robust IOP-lowering effect of NCX 470.

2024-08-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Article

作者: Mansberger, Steven ; Ziebell, Sara ; Lopez, Krisi ; Hubatsch, Doug ; Fechtner, Robert ; Mulaney, Jay ; Branch, James

PURPOSE:

To compare intraocular pressure (IOP)-lowering efficacy and safety of NCX 470, a nitric oxide (NO)-donating bimatoprost, to latanoprost in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

DESIGN:

Prospective, phase 3, randomized, adaptive dose-selection, double-masked, parallel-group trial.

METHODS:

691 subjects with OAG or OHT and unmedicated IOP ≥26 mmHg at 8AM, ≥24 mmHg at 10AM, and ≥22 mmHg at 4PM in the study eye were randomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%. An interim analysis was performed to select the final dose of NCX 470. We evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM and 4PM at 2 weeks, 6 weeks, and 3 months.

RESULTS:

661 subjects were analyzed; IOP was significantly reduced at all on-treatment time points, with reductions ranging from 8.0 to 9.7 mmHg (P < .0001 at each time point) in the NCX 470 0.1% group. Mean IOP reductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantly greater (P < .05) at 4 of the 6 time points. The most common adverse event was conjunctival/ocular hyperemia.

CONCLUSION:

The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.

137

项与格贝前列素相关的新闻（医药）

2026-08-31

·PRNewswire

Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension

Investigational K-911 is a once-daily nitric oxide-donating bimatoprost eye drop designed to lower intraocular pressure NDA is supported by two pivotal Phase 3 trials FDA assigns PDUFA target action date of April 30, 2027 MONTGOMERY, Ala., Aug. 27, 2026 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. (KPA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for K-911 (bimatoprost grenod, also known as NCX 470), an investigational topical ophthalmic monotherapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2027. "The FDA's acceptance of the NDA for K-911 marks an important milestone as we work toward bringing a potential new treatment option to people living with open-angle glaucoma or ocular hypertension," said Joe Barna, CPA, Chief Executive Officer and President of KPA. "We're proud to bring Kowa's decades of global ophthalmology experience to the U.S. eye care community, and we look forward to working with the FDA throughout the review process." K-911 is an investigational, once-daily nitric oxide-donating bimatoprost monotherapy formulated as a sterile ophthalmic solution and engineered to lower IOP through two distinct aqueous humor outflow pathways. Nitric oxide is intended to enhance conventional outflow through the trabecular meshwork-Schlemm's canal pathway, while bimatoprost enhances uveoscleral outflow. The NDA is supported by two pivotal Phase 3 clinical trials, Mont Blanc and Denali, which evaluated K-911 0.1% against latanoprost 0.005%, a widely used prostaglandin analog, in patients with OAG or OHT. Despite the availability of multiple treatment options, achieving and maintaining appropriate IOP control remains an important treatment goal for patients with OAG or OHT, with individual needs varying from patient to patient and over time. In February 2024, Kowa Company, Ltd. and Nicox S.A. entered into an exclusive licensing agreement for the development, manufacturing and commercialization of K-911 in Japan, followed by an agreement in July 2025 granting Kowa rights to develop and commercialize K-911 in the United States and other licensed territories. Nicox, which discovered and developed K-911 and led the Mont Blanc and Denali Phase 3 trials, continues to provide development expertise and support, while Kowa is responsible for U.S. regulatory and commercialization activities. The FDA's acceptance of the K-911 NDA for filing marks the next regulatory milestone for K-911 in the U.S. as the application proceeds through FDA review. Following confirmation of a PDUFA target action date of April 30, 2027, Kowa anticipates a U.S. commercial launch in the second half of 2027, subject to approval. About Glaucoma and Ocular Hypertension Glaucoma is a progressive eye disease that can cause irreversible optic nerve damage leading to vision loss and potential blindness.1,2 More than 4.2 million adults in the U.S. live with glaucoma, with open-angle glaucoma representing the most common form of the disease.3 Lowering intraocular pressure is the only proven approach to slowing glaucoma disease progression.1,2 Ocular hypertension is characterized by elevated intraocular pressure without detectable optic nerve damage or vision loss.4 Although ocular hypertension may not cause symptoms, elevated IOP is an important risk factor for the development of glaucoma.4 An estimated 3-6 million people in the U.S. live with ocular hypertension.4 About K-911 K-911 (bimatoprost grenod), also known as NCX 470, is an investigational, once-daily nitric oxide-donating bimatoprost eye drop being developed for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The NDA is supported by the Phase 3 Mont Blanc and Denali trials. K-911 is an investigational product and has not yet been approved by the FDA. Kowa holds exclusive rights to develop and commercialize K-911 in the U.S. About Kowa Pharmaceuticals America, Inc. Kowa Pharmaceuticals America, Inc. (KPA) is a Montgomery, Alabama-based specialty pharmaceutical company with 18 years of experience developing and commercializing pharmaceuticals for the U.S. market. As part of Kowa Company, Ltd. (KCL), KPA is building on Kowa's decades of global ophthalmology expertise as it expands its presence in the U.S. eye care community. For more information, please visit . References Cleveland Clinic. (2024, November 12). Glaucoma: What it is, symptoms, causes, types & treatment. Cleveland Clinic. National Eye Institute. (2025, November 26). Glaucoma. U.S. Department of Health and Human Services. Seminara, L. (2025, February 1). Updated prevalence of glaucoma in the United States. EyeNet Magazine. American Academy of Ophthalmology. Cleveland Clinic. (2022, December 19). Ocular hypertension: Causes, symptoms & treatment. Cleveland Clinic. Christian Vaughn, [email protected] SOURCE Kowa Pharmaceuticals America, Inc. 21% more press release views with Request a Demo

临床3期引进/卖出申请上市

2026-08-27

·PRNewswire

New Drug Application for "K-911" Targeting Patients with Glaucoma and Ocular Hypertension Accepted for Filing in the U.S., Food and Drug Administration

NAGOYA, Japan, Aug. 27, 2026 /PRNewswire/ -- Kowa Company, Ltd. (hereafter referred to as "Kowa") is developing K-911 for the indication of reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension through its affiliated company engaged in pharmaceutical development in the United States, Kowa Research Institute, Inc. (headquartered in North Carolina, USA). Kowa today announced that the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) on June 30, 2026 has been accepted for filing. The FDA will conduct its review of the NDA with a target action date of April 30, 2027, under the Prescription Drug User Fee Act (PDUFA). K-911 (bimatoprost grenod) is a novel prostanoid FP receptor agonist including the moiety donating nitric oxide (NO), discovered by Nicox S.A. (hereafter referred to as "Nicox"), a French pharmaceutical company focused on the research and development of ophthalmic prescription drugs. Kowa entered into an exclusive license agreement with Nicox for development, manufacturing, and commercialization in Japan in February 2024, and for the rest of the world excluding China, Taiwan, Korea, and Southeast Asia in July 2025. "K-911" has demonstrated a potent IOP-lowering effect by promoting aqueous humor outflow through two pathways: the conventional outflow pathway via the trabecular meshwork–Schlemm's canal mediated by NO, and the unconventional outflow pathway via the uveoscleral mediated by bimatoprost. Through the development of K-911, Kowa aims to provide a new treatment option for patients with glaucoma and ocular hypertension. Media Contact: Kowa Company, Ltd. Public Relations Department (Japanese inquiries only) TEL: +81-3-3279-7392 SOURCE Kowa Company Ltd. 21% more press release views with Request a Demo

2026-08-27

·BioSpace

Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma

Press Release Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma FDA sets Prescription Drug User Fee Act (PDUFA) review response date by 30 April 2027 Two NDAs filed in major markets, with commercial partners in place for expected launches from H2 2027 onwards Milestone payment due on U.S. NDA approval plus royalties on sales NCX 470 Phase 3 program ongoing in Japan in support of approval Q&A available on Nicox’s website August 27, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for NCX 470 (bimatoprost grenod; also known as K-911 in Kowa’s publications) for filing and set 30 April 2027 as the Prescription Drug User Fee Act (PDUFA) date 1 for a response on review of the dossier. FDA acceptance confirms that the application is sufficiently complete for formal review and represents an important regulatory milestone toward potential approval. The NCX 470 NDA in the U.S. was submitted by Nicox’s exclusive U.S. licensee, Kowa, on June 30, 2026, and a milestone payment will be due upon approval. NCX 470 is a nitric oxide-donating bimatoprost eye drop for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. “The FDA’s acceptance of the NCX 470 NDA for filing is the next key step towards the approval of NCX 470 in the U.S., which would lead to a commercial launch in the second half of 2027. NCX 470 NDAs are now filed in two key markets, the U.S. and China. Subject to regulatory approval, we have clear paths to commercialisation with our partners, Kowa and Ocumension, respectively. Both partners have established commercial organisations in place to support launch of NCX 470 swiftly after approval is granted. U.S. NDA approval triggers a milestone payment for Nicox, and royalties on sales would generate a new recurrent revenue stream,” said Gavin Spencer, Chief Executive Officer of Nicox. The NDA submission was based on positive results from the Mont Blanc and Denali Phase 3 clinical trials, which together were designed to meet regulatory requirements for efficacy and safety in support of approval in the United States and China. These trials demonstrated that NCX 470 achieved clinically meaningful reductions in IOP of up to 10mmHg with a favourable safety profile. Key Upcoming NCX 470 Milestones Phase 3 clinical program in Japan: ongoing U.S. FDA Decision: PDUFA date 30 April 2027 U.S. Launch: targeted in H2 2027, subject to FDA approval NDA approval in China: NDA submitted August 2026 For further information on our commercialization partners in the U.S. and China, visit the websites of Kowa Pharmaceuticals America and Ocumension Therapeutics . About NCX 470 NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. NCX 470 has completed two Phase 3 clinical trials, Mont Blanc and Denali, designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com Media Sophie Baumont Rose Piquante Consulting T +33 6 27 74 74 49 sophie.baumont@rosepiquante-consulting.com Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “ Rapport Annuel 2025 ” which are available on Nicox’s website ( ). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA). Attachment EN_NCX470PDUFADateSeptember2026_PR_FINAL

临床3期申请上市临床结果引进/卖出

100 项与格贝前列素相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
开角型青光眼	申请上市	-	Kowa Co., Ltd.	2026-07-01
高眼压症	临床3期	中国	苏州欧康维视生物科技有限公司	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04630808 (Denali, NEWS) 人工标引	临床3期	开角型青光眼 \| 高眼压症	696	NCX 470 0.1%	廠糧遞夢衊衊齋鑰廠膚(糧製積築淵簾鹹鑰獵艱) = Mean IOP reductions from baseline ranged from 7.9 to 10.0 mmHg with NCX 470 0.1% compared to 7.1 to 9.8 mmHg with latanoprost, measured at 8 AM and 4 PM across week 2, week 6, and month 3 visits. In a prespecified secondary analysis, NCX 470 achieved statistically significant superiority (p<0.05) at 3 of 6 timepoints, and numerically greater reductions at 5 of 6 timepoints, with differences up to 0.8 mmHg in favor of NCX 470. 淵齋窪築遞製廠壓選顧 (淵鏇製鑰齋襯醖廠鹽簾 ) 更多	非劣	2025-08-21
				Latanoprost 0.005%
NCT04445519 (MONT BLANC, CTgov)	临床3期	开角型青光眼	691	NCX 470 0.1% (initial phase of trial) (NCX 470 0.1%)	餘範簾範衊鬱獵製艱膚(範鏇觸鹹淵積獵簾衊衊) = 夢願築網繭顧蓋蓋鹽遞顧艱襯顧願艱衊願廠鏇 (膚膚醖觸窪製鑰構艱廠, 3.443) 更多	-	2025-05-30
				Latanoprost (Latanoprost 0.005%)	餘範簾範衊鬱獵製艱膚(範鏇觸鹹淵積獵簾衊衊) = 築壓襯鹽淵壓壓衊蓋淵顧艱襯顧願艱衊願廠鏇 (膚膚醖觸窪製鑰構艱廠, 3.349) 更多
NCT05938699 (Whistler, GlobeNewswire) 人工标引	临床3期	高眼压症	18	NCX 470	艱鹽鹹廠衊製鹽醖觸選(淵艱壓膚壓襯製窪網觸) = Changes in aqueous humor flow rate trended towards significance vs. placebo (p=0.072). Outflow facility was positive at 1 pm (p=0.081), significant at 3 pm (p=0.001), as was the diurnal outflow (p=0.004). 壓繭夢壓鬱選遞夢憲憲 (艱襯糧鏇選蓋獵鹽鑰築 )	积极	2025-05-14
				Placebo
NCT04445519 (MONT BLANC, Literature) 人工标引	临床3期	开角型青光眼 \| 高眼压症	103	NCX 470NCX 470 0.065 %	餘鹽糧夢範構壓遞積糧(壓衊遞淵製簾廠壓繭獵) = The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). 遞壓觸選窪餘齋膚廠齋 (繭餘窪遞鏇觸觸顧鹽鏇 )	积极	2024-12-01
				NCX 470NCX 470 0.1 %
NCT04445519 (MONT BLANC, Pubmed \| Contemp Clin Trials)	临床3期	高眼压症 \| 开角型青光眼	103	NCX 470 0.065%	積願衊鏇壓膚築顧膚鑰(蓋繭襯淵醖製膚遞憲繭) = The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). 鬱蓋蓋壓積鹹簾構憲築 (鹽艱壓糧糧築艱夢製顧 ) 更多	积极	2024-12-01
				Latanoprost 0.005%
NCT03657797 (Dolomites, CTgov)	临床2期	开角型青光眼	656	NCX 470 (NCX 470 0.021%)	網願廠簾鏇齋獵獵糧窪(壓願窪憲襯廠淵觸鑰窪) = 觸膚襯鑰夢餘築衊壓膚醖遞築夢醖製夢鹹衊鹽 (醖範鹽糧齋鑰蓋築選鑰, 2.606) 更多	-	2022-12-08
				NCX 470 (NCX 470 0.042%)	網願廠簾鏇齋獵獵糧窪(壓願窪憲襯廠淵觸鑰窪) = 製齋膚繭廠醖網夢鏇窪醖遞築夢醖製夢鹹衊鹽 (醖範鹽糧齋鑰蓋築選鑰, 2.511) 更多
NCT04445519 (Mont Blanc, Corporate Publications) 人工标引	临床3期	青光眼	691	NCX 470	獵鑰艱簾觸繭積繭顧鏇(構鹽鹽齋鑰遞製積鬱獵) = 艱鏇壓鹹繭積築鹽築鏇鑰鏇糧鬱衊願網壓壓襯 (獵襯鬱鏇鏇構夢觸鬱廠 ) 更多	非劣	2022-10-31
				Latanoprost	獵鑰艱簾觸繭積繭顧鏇(構鹽鹽齋鑰遞製積鬱獵) = 選齋鏇選齋憲鹹選鹽鹽鑰鏇糧鬱衊願網壓壓襯 (獵襯鬱鏇鏇構夢觸鬱廠 ) 更多
NCT03657797 (Dolomites, AAO2020)	临床2期	低眼压	433	NCX 470 0.021%	鑰鬱膚選膚廠網選膚壓(膚醖鏇壓範繭膚鏇醖廠) = The most common adverse event was conjunctival hyperemia. There were no treatment-related serious adverse events or treatment-related systemic adverse events 艱餘鬱範齋顧繭積齋廠 (繭觸顧糧範糧築壓鏇齋 )	积极	2020-11-13
				NCX 470 0.065%
NCT03657797 (Dolomites, GlobeNewswire) 人工标引	临床2期	青光眼	433	NCX-470	廠積醖鏇構窪網餘網廠(築窪積憲齋蓋選壓積積) = 鑰繭築築餘壓觸淵糧積網淵遞齋糧餘獵鹽構觸 (醖蓋積製齋鏇淵艱範遞 ) 更多	积极	2019-10-02
				Latanoprost	廠積醖鏇構窪網餘網廠(築窪積憲齋蓋選壓積積) = 醖廠鏇選廠壓膚選遞艱網淵遞齋糧餘獵鹽構觸 (醖蓋積製齋鏇淵艱範遞 ) 更多